SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kennedy Lawrence T. Jr

(Last) (First) (Middle)
1700 MADISON ROAD, SUITE 200

(Street)
CINCINNATI OH 45206

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/23/2024 M 1,739,120 A (1) 12,267,873 I By: Lawrence T. Kennedy, Jr. Perpetuity Trust UAD 6/30/16
Common Stock 05/23/2024 M 2,608,720 A (1) 2,775,386 I By: KFDI-B LLC
Common Stock 10,304,824(2) I By: Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (3) 05/21/2024 A 46,686 (4) (4) Common Stock 46,686 $0 46,686(5) D
Stock Options (Right to Buy) $1.57 05/21/2024 A 37,050 (6) 05/20/2034 Common Stock 37,050 $0 37,050 D
Series A Non-Voting Convertible Preferred Stock (1) 05/23/2024 M 43,478 (1) (1) Common Stock 1,739,120 $0 0 I By: Lawrence T. Kennedy, Jr. Perpetuity Trust UAD 6/30/16
Series A Non-Voting Convertible Preferred Stock (1) 05/23/2024 M 65,218 (1) (1) Common Stock 2,608,720 $0 0 I By: KFDI-B LLC
Explanation of Responses:
1. The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.
2. Reported amount has been adjusted to reflect the September 18, 2023 transfer of 687,515 shares of Common Stock previously held by the Lair BDSX GRAT 2022-3.2 to the Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 and the March 11, 2024 transfer of 34,526 shares of Common Stock previously held by the Lair BDSX GRAT 2022-3.2 to the Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 (the "March 11, 2024 Transfer"), each of which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Exchange Act. The Lair BDSX GRAT 2022-3.2 ceased to beneficially own any shares of Common Stock following the March 11, 2024 Transfer.
3. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock.
4. These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.
5. Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
6. This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.
/s/ Robin H. Cowie as Attorney-in-Fact for Lawrence T. Kennedy, Jr. 05/23/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Biodesix (NASDAQ:BDSX)
過去 株価チャート
から 5 2024 まで 6 2024 Biodesixのチャートをもっと見るにはこちらをクリック
Biodesix (NASDAQ:BDSX)
過去 株価チャート
から 6 2023 まで 6 2024 Biodesixのチャートをもっと見るにはこちらをクリック